Regulus shares spike on a high success rate for RG-101 hep C combos

John Carroll Can Regulus still make a splash in the increasingly crowded hepatitis C drug market? The biotech says yes, backing up its case for RG-101 with interim Phase II data that ...

EMA: Faulty device didn’t distort study findings for Bayer’s Xarelto

Carly Helfand Last December, European regulators said they were no longer sure whether results from a trial of Bayer's new-age clot-buster Xarelto were accurate ...

Trump crosses party lines to back Medicare drug-price negotiation

Alok Saboo Democratic presidential candidates Hillary Clinton and Bernie Sanders have already taken aim at pharma, talking up plans to give Medicare power to negotiate drug prices. ...

Novartis CEO Jimenez sees U.S. pricing power draining away

Carly Helfand Remember the days when drugmakers could raise prices without sparking political pushback? Novartis CEO Joe Jimenez does–and he says they're not coming back. FiercePharma ...

A look at pharma’s many TV spokes-creatures

Damian Garde Over the past decade, pharma companies have increasingly relied on animated characters to advertise their products, using cute, quaint or questionable creatures to illustrate ...

Novartis adds 100 jobs at Lek site in Slovenia as it muscles up on biosimilars

Eric Palmer Novartis was the first drugmaker to get a biosimilar approved in the U.S. and has set itself up to be a major player in the growth of the biologic copies. That is going ...

Valeant’s ill CEO Pearson on the ‘road to recovery,’ but still no timeline for his return

Carly Helfand Valeant's pneumonia-stricken CEO, J. Michael Pearson, is on the mend, according to a letter he penned to his colleagues on Monday. But as to when he'll be back ...

UPDATED: Hedge fund’s attack on troubled Zafgen draws blood

John Carroll These days, while success and victory still have 1,000 fathers, failure and defeat have its outspoken champions as well. FierceBiotech News

Editas tests CRISPR/Cas9 enthusiasm–and a turbulent market–with $122M IPO

John Carroll Despite facing one of the worst markets for biotech stocks in recent memory, Editas Medicine has taken another big step forward in its quest to raise some big bucks through ...

Amgen’s Kyprolis wins ‘backbone therapy’ FDA nod after trumping Velcade in trial

Carly Helfand Back in March, Amgen's Kyprolis posted impressive results in a head-to-head trial with Takeda behemoth Velcade–and now, those results have helped it grab an ...

‘I have constitutional rights,’ tweets Martin Shkreli, defying Senate subpoena

John Carroll Over the past three months, Martin Shkreli rarely passed up an opportunity to publicly mock his critics or justify a 5000%-plus price hike on a 62-year-old generic. But ...

Abingworth tees up a unique, $105M co-development fund for PhIII deals

John Carroll The international team at Abingworth likes investing in co-development programs, backing two companies that specialize in taking on the risk and cost of Phase III in exchange ...
Page 1 of 3212345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS